The Role of SLRP-Proteoglycans in Osteosarcoma Pathogenesis

REFERENCES

• Iozzo R.V. The biology of the small-leucine-rich Proteoglycans. J. Biol. Chem. 1999; 274: 18843–18846
   PubMed Web of Science ®Google Scholar
• Kobe B., Kajava A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 2001; 11: 725–732
   PubMed Web of Science ®Google Scholar
• Weber I.T., Harrison R.W., Iozzo R.V. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem., 271: 31767–31770
   PubMed Web of Science ®Google Scholar
• Scott P.G., Grossman J.G., Dodd C.M., Sheehan J.K., Bishop P.N. Light and X-ray scattering show decorin to be a dimer in solution. J. Biol. Chem. 2003; 281: 15633–18359
   Google Scholar
• Kajava A.V. Structural diversity of leucin-rich proteins. J. Mol. Biol. 1998; 277: 519–577
   PubMed Web of Science ®Google Scholar
• Waddington R.J., Roberts H.C., Sugars R.V., Schönherr E. Differential roles for small-leucine-rich proteoglycans in bone formation. Eur. Cell. Mater. 2003; 6: 12–21
   PubMedGoogle Scholar
• Hocking A.M., Shinomura T., McQuillan D.J. Leucine-rich repeat proteoglycans of the extracellular matrix. Matrix Biol. 1998; 17: 1–8
   PubMed Web of Science ®Google Scholar
• Iozzo R.V., Danielson K.G. Transcriptional and posttranscriptional regulation of proteoglycan gene expression. Prog. Nucleic Acid Res. Mol. Biol. 1999; 62: 19–53
   PubMed Web of Science ®Google Scholar
• Vogel K.G., Trotter J.A. The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Collagen Relat. Res. 1987; 7: 105–114
   PubMedGoogle Scholar
• Kresse H., Liszio C, Schönherr E, Fisher L.W. Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen. J. Biol. Chem. 1997; 2: 18404–18410
   Google Scholar
• Kresse, H., Schönherr E. Proteoglycans of the extracellular matrix and growth control. J. Cell Physiol. 2001; 3: 266–274
   Google Scholar
• Vogel W., Gish G.D, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Moll. Cell 1997; 1: 13–23
   PubMed Web of Science ®Google Scholar
• Jaffe N., Carrasco H., Raymond K., Ayala A., Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?. Cancer 2002; 10: 2202–2210
   Google Scholar
• Benayahu D., Shur I., Meller I., Issakow J. Cellular and molecular properties associated with osteosarcoma cells. J. Cell Biochem. 1998; 84: 108–114
   Google Scholar
• Nikitovic D., Tsatsakis A.M, Karamanos N.K, Tzanakakis G.N. The effects of genistein on the synthesis and distribution of glycosaminoglycans/proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res. 2003; 23: 459–464
   PubMed Web of Science ®Google Scholar
• Tzanakakis G.N., Nikitovic D, Katonis P, Kanakis I, Karamanos N.K. Expression and distribution of N-acetyl and N-glycolylneuraminic acids in secreted and cell-associated glycoconjugates by two human osteosarcoma cell lines. Biomed. Chromatogr. 2006; 21: 406–409
   Web of Science ®Google Scholar
• Schulz A., Loreth B, Battmann A., Knoblauch B, Stahl U, Pollex U., Bohle R.M. Bone matrix production in osteosarcoma. Verh. Dtsch. Ges. Pathol. 1998; 82: 144–153
   PubMedGoogle Scholar
• Mintz A.B., et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. 2005; 5: 1748–1754
   Google Scholar
• Santra M., Mann D.M, Mercer E.W, Skorski T, Calabretta B, Iozzo R.V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 1997; 1: 149–157
   Google Scholar
• Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281–284
   PubMed Web of Science ®Google Scholar
• Grant D.S, Yenisey C, Rose R.W, Tootell M, Santra M, Iozzo R.V. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002; 31: 4765–4777
   Google Scholar
• Merle B., Durussel L., Delmas P.D., Clézardin P. Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J. Cell Biochem. 1999; 75: 538–546
   PubMed Web of Science ®Google Scholar
• Velez-Yanguas M., et al. 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J. Clin. Endocrinol. Metab. 1996; 1: 93–99
   Google Scholar
• Wegrowski Y., Gillery P, Kotlarz G, Perreau C, Georges N., Maquart F.X. Modulation of sulfated glycosaminoglycan and small proteoglycan synthesis by the extracellular matrix. Mol. Cell Biochem. 2000; 1–2: 125–131
   Google Scholar
• Groth S., Schulze M, Kalthoff H, Fändrich F., Ungefroren H. Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J. Biol. Chem. 2005; 280: 33190–33199
   PubMed Web of Science ®Google Scholar
• Nikitovic D., Berdiaki A., Zafiropoulos A., Katonis P., Tsatsakis A., Karamanos N.K., Tzanakakis G.N. Lumican expression is positively correlated with human osteosarcoma cell differentiation and negatively with their growth. FEBS J. 2008; 275: 350–361
   PubMed Web of Science ®Google Scholar
• Raouf A., Ganss B, McMahon C., Vary C., Roughley P.J., Seth A. Lumican is a major proteoglycan component of the bone matrix. Matrix Biol., 4: 361–367
   Google Scholar
• Yu Y., Harris R.I, Yang J.L, Anderson H.C, Walsh W.R. Differential expression of osteogenic factors associated with osteoinductivity of human osteosarcoma cell lines. J. Biomed. Mater. Res. A 2004; 70: 122–128
   PubMedGoogle Scholar
• Naito Z. The role of small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J. Nippon Med. Sch. 2005; 72: 137–145
   PubMedGoogle Scholar
• Franchi A., Arganini L., Baroni G., Calzolari A., Capanna R., Campanacci D., Caldora P., Masi L., Brandi M.L., Zampi G. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J. Pathol. 1998; 185: 284–289
   PubMed Web of Science ®Google Scholar
• Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis A.D, Karamanos N.K, Tzanakakis G.N. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 2006; 58: 47–53
   PubMed Web of Science ®Google Scholar
• Funderburgh J.L., Funderburgh M.L, Mann M.M., Corpuz L., Roth M.R. Proteoglycan expression during transforming growth factor beta -induced keratocyte-myofibroblast transdifferentiation. J. Biol. Chem. 2001; 276: 44173–44178
   PubMed Web of Science ®Google Scholar
• Hao J., Ju H, Zhao S, Junaid A, Scammell-La Fleur T., Dixon I.M. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J. Mol. Cell Cardiol. 1999; 31: 667–678
   PubMed Web of Science ®Google Scholar
• Cabello-Verrugio C., Brandan E. A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J. Biol. Chem. 2007; 282: 18842–18850
   PubMed Web of Science ®Google Scholar